Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 4/20 | 0.33 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | NQO2 | P16083 | 1/20 | 0.32 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1992129 | 0.88 | IDO1 (0.38) | MAP2K1KITBRAFMAP2K2 | |
| SCHEMBL1987059 | 0.84 | MAP2K1 (0.35) | MAP2K1MAPTBRAFABCB11NQO2 | |
| SCHEMBL2049340 | 0.82 | MAP2K1 (0.37) | TDP1MAP2K1MAPTBRAF | |
| SCHEMBL12540057 | 0.77 | MAP2K1 (0.38) | MAP2K1MAPTABCB11NQO2MAP2K2 | |
| SCHEMBL12539792 | 0.74 | MAP2K1 (0.37) | MAP2K1MAP2K2 | |
| SCHEMBL15129483 | 0.74 | BRAF (0.35) | TDP1MAP2K1MAPTKITBRAF | |
| SCHEMBL1341935 | 0.72 | BRD4 (0.34) | MAP2K1MAPTBRAF | |
| SCHEMBL1992506 | 0.72 | MAP2K1 (0.36) | MAP2K1MAP2K2 | |
| SCHEMBL1981292 | 0.72 | MAP2K1 (0.43) | MAP2K1MAP2K2 | |
| SCHEMBL1343639 | 0.72 | TDP1 (0.41) | TDP1MAP2K1MAPTKITBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | claimed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | claimed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | claimed |
| EP-2509964-B1 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2014-04-30 | — | — | EP | disclosed |
| US-8614239-B2 | Heterocyclic sulfonamide derivatives | NOVARTIS AG (CH) | 2013-12-24 | — | — | US | disclosed |
| EP-2509964-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | Novartis AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
| WO-2011070030-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291151-A1 | 1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR | TACR1, HTR3A, HTR3C | TDP1 1383/4885ALDH1A1 887/4885MAP2K1 3844/4885 |
| US-20120245209-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES | BRAF, NRAS, MAP3K1 | TDP1 2643/4885ALDH1A1 510/4885MAP2K1 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.